Replication of the Heads Up Atopic Dermatitis Trial With Registry Data
Launched by TECHNISCHE UNIVERSITÄT DRESDEN · Apr 14, 2025
Trial Information
Current as of September 06, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of two treatments, upadacitinib and dupilumab, for people with moderate to severe atopic dermatitis (AD), a skin condition that causes itching and rashes. The main goal is to see if these treatments can help improve symptoms significantly after 16 weeks, as measured by a specific score called EASI. Additionally, the trial will look at how patients feel about their condition and treatments through surveys.
To be eligible for this trial, participants must have had chronic atopic dermatitis for at least three years, have a certain level of skin involvement, and meet specific scoring criteria. The trial is currently active but not recruiting new participants. If selected, participants will receive one of the two treatments and will be monitored to track their progress and experiences. This study aims to provide more information on how well these treatments work compared to each other, which can help improve care for individuals with atopic dermatitis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chronic AD with onset of symptoms at least 3 years prior to baseline
- • Meets UK working party criteria
- • EASI score ≥ 16
- • ≥ 10% body surface area (BSA) of AD involvement at baseline ("therapy start") visit
- Exclusion Criteria:
- • contraindications according to upadacitinib or dupilumab labeling
About Technische Universität Dresden
Technische Universität Dresden (TU Dresden) is a leading research institution in Germany, renowned for its commitment to advancing scientific knowledge and innovation across various disciplines, including medicine and healthcare. As a clinical trial sponsor, TU Dresden leverages its cutting-edge research facilities and interdisciplinary expertise to facilitate the development of novel therapeutic interventions and improve patient outcomes. The university fosters collaboration among academic, clinical, and industry partners, ensuring rigorous adherence to ethical standards and regulatory requirements in the conduct of clinical research. Through its dedication to excellence and research-driven initiatives, TU Dresden plays a pivotal role in translating scientific discoveries into practical applications that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dresden, Saxony, Germany
Patients applied
Trial Officials
Jochen M Schmitt
Principal Investigator
Center for Evidence-based Healthcare, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported